Telomir Pharmaceuticals Added To Russell 3000 And Russell Microcap Indexes

7/2/24 8:34:53 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $TELO alert in real time by email

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA's protective telomere caps as a potential treatment for age-related conditions, today announced that the Company has been added as a member of the broad-market Russell 3000® and the Russell Microcap® Indexes, effective July 1, as part of the 2024 Russell indexes reconstitution.

Get the next $TELO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TELO

Date	Price Target	Rating	Analyst

More analyst ratings

$TELO
Market Insights

Live Market Insights

Telomir Pharmaceuticals Added To Russell 3000 And Russell Microcap Indexes
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA's protective telomere caps as a potential treatment for age-related conditions, today announced that the Company has been added as a member of the broad-market Russell 3000® and the Russell Microcap® Indexes, effective July 1, as part of the 2024 Russell indexes reconstitution.
7/2/24 8:34:53 AM ET
$TELO
Biotechnology: Pharmaceutical Preparations
Health Care
Telomir Pharmaceuticals Commences Two Milestones For Telomir-1
Commences the study, The Safety of Telomir-1 when Administered Orally to Geriatric Laboratory Beagle Dogs for 63 Consecutive Days study to evaluate the safety of Telomir-1 on geriatric canines Began geriatric canine study on May 28th with initial dosing of Telomir-1 – All Animals Tolerated Dosing Well – Data will explore the potential for treatment of age-related conditions
5/30/24 8:36:57 AM ET
$TELO
Biotechnology: Pharmaceutical Preparations
Health Care
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Predictive Oncology (NASDAQ:POAI) shares rose 36.4% to $1.95 during Tuesday's after-market session. The company's market cap stands at $7.9 million. Brainstorm Cell (NASDAQ:BCLI) shares moved upwards by 18.25% to $0.45. The company's market cap stands at $30.5 million. Telomir Pharmaceuticals (NASDAQ:TELO) stock increased by 12.92% to $7.34. The market value of their outstanding shares is at $217.3 million. NRX Pharmaceuticals (NASDAQ:NRXP) stock increased by 11.24% to $2.87. The market value of their outstanding shares is at $30.1 million. TransMedics Gr (NASDAQ:TMDX) shares moved upwards by 11.02% to $104.51. The company's market cap stands at $3.4 billion. As per the press re
4/30/24 4:31:25 PM ET
$AKTX
$BCLI
$CCM
$CVRX
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Medical/Nursing Services

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
MIAMI, FL / ACCESSWIRE / November 21, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced groundbreaking preclinical results confirming the efficacy of Telomir-1, a compound designed to effectively turn back the biological clock and support longevity.Using advanced in vivo microfluidic technology, in collaboration with Nagi Biosciences SA, the study demonstrates significant age-reversal effects in aging model organisms treated with Telomir-1, effectively turning back the biological clock. These effects include an extended healthy lifespan, improved mobility, and a measurable reversal of age-related decli
11/21/24 7:00:00 AM ET
$TELO
Biotechnology: Pharmaceutical Preparations
Health Care
Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday
Interview to Air Sunday, September 29, 2024 at 5:30 PM EST on Fox Business NetworkMIAMI, FL / ACCESSWIRE / September 26, 2024 / Telomir Pharmaceuticals (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company seeking to lead developments in longevity science through the treatment of age-related conditions, is proud to announce that the Telomir will be featured on Health Uncensored with Dr. Drew this Sunday, September 29, 2024 at 5:30 PM EST / 2:30 PM PT on Fox Business Network.In this episode, Telomir Pharmaceuticals' Special Advisor, Dr. Michael F. Roizen, MD, Emeritus Chief Wellness Officer at Cleveland Clinic, will join Dr. Drew Pinsky to discuss the science o
9/26/24 4:00:00 PM ET
$TELO
Biotechnology: Pharmaceutical Preparations
Health Care
Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications
MIAMI, FL / ACCESSWIRE / September 4, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage company seeking to lead developments in longevity science through the treatment of age-related conditions, is pleased to announce the appointment of Dr. Itzchak Angel as Chief Scientific Advisor.Dr. Angel, in collaboration with Telomir's senior management, will look to expedite the pre-clinical and clinical path of Telomir's lead product candidate, Telomir-1, a novel small molecule designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process.Telomir is presently optimizing drug production and forming strategic partnersh
9/4/24 7:30:00 AM ET
$TELO
Biotechnology: Pharmaceutical Preparations
Health Care

Telomir Pharmaceuticals Added To Russell 3000 And Russell Microcap Indexes

Chat with this insight

Recent Analyst Ratings for
$TELO

$TELO
Market Insights

Live Market Insights